secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-04-12T23:59:59+00:00
Accession:  0001193125-23-098539
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea cuts 83% of workforce, explores strategic alternatives after mixed trial data
--------------------------------------------------------------------------------

- Workforce reduced by 50 (~83% of headcount) to ~10 employees; $6.2M restructuring charges expected in Q2 2023.
- CBO Michael Hanley and CMO Linda Neuman depart effective April 14, 2023.
- Interim Phase 1/2 pegtarviliase trial: dose-dependent homocysteine reduction in cohorts 1–2 but not consistent in cohort 3; ADAs observed.
- Company engages Wedbush Securities to explore strategic alternatives including sale or merger; no timetable set.
- Pegzilarginase MAA under EMA review with potential EU decision in late 2023; partnered with Immedica.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523098539/0001193125-23-098539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523098539/d485603d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-098539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer